ClinicalTrials.gg
Enrolling by invitationNCT07058376Updated Nov 19, 2025

Clinical Research of Effectiveness and Safety of Herbal Medicine Strategy for Chronic Low Back Pain

An interventional study of Herbal Medicine Strategy and Standard Korean Medicine Treatment in Chronic Low-back Pain (cLBP), sponsored by Jaseng Medical Foundation. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Jaseng Medical Foundation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
19 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Low Back Pain by Jaseng Medical Foundation — 4 open to participants now, 5 under way, none of them phase 3. Low Back Pain · Jaseng Medical Foundation.

Started
2025
with 1 other
No phase
8 of 11
3 open now
Registered
8th of 11
by date

Among the 11 studies in Low Back Pain by Jaseng Medical Foundation, this one is one of 2 that started in 2025, is one of 8 with no phase, and was the 8th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

4 of the 11 studies in Low Back Pain by Jaseng Medical Foundation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 19 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Low Back Pain by Jaseng Medical Foundation, or all of them as a file.
02

Study summary

This study is a pragmatic multicenter randomized controlled trial evaluating the effectiveness and safety of herbal medicine strategy for chronic low back pain, using standard Korean medicine treatment as the control.

Read the detailed description

0. Background Chronic low back pain (CLBP) is a common musculoskeletal disorder often managed in Korean medicine. This study aims to evaluate the effectiveness and safety of herbal medicine strategies for CLBP within a real-world clinical setting. It was initiated as part of a national research project to generate evidence for insurance coverage of herbal prescriptions.

  1. Patient Recruitment and Screening Phase A total of 150 patients with CLBP lasting more than 3 months will be recruited across seven Korean medicine hospitals. Patients will be randomly assigned (1:1) to either the herbal medicine strategy group or the standard Korean medicine treatment group. Randomization will be prospective and pragmatic, with no pre-specified protocol for individual treatments.
  2. Treatment and Evaluation Phase

    Experimental Group (Herbal Medicine Strategy): Participants receive individualized herbal prescriptions based on clinical judgment. Medication is prescribed every 10 days for a total of 30 days.

    Control Group (Standard KM Treatment): Participants receive acupuncture, electroacupuncture, cupping, moxibustion, infrared therapy, and physical therapy twice weekly for 5 weeks, with slight variations allowed based on symptom severity.

    Treatment details and frequencies will be recorded in CRFs and assessed during and after the intervention.

  3. Follow-Up Phase Participants will be followed up after the treatment period to assess outcomes. Evaluation includes pain intensity, affected areas, quality of life, and treatment adherence.
  4. Monitoring Although the study is investigator-initiated, third-party monitoring will be conducted in accordance with HRPP and Korean GCP guidelines to ensure protocol compliance and data integrity.
03

Conditions studied

  • Chronic Low-back Pain (cLBP)

Browse trials for

Keywords

  • herbal medicine
  • chronic back pain
04

Who can participate

Ages eligible
19 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals experiencing low back pain for more than 3 months.
  • Low back pain Numeric Rating Scale (NRS) score of 5 or higher.
  • Aged 19 years or older and younger than 70 years.
  • Individuals who voluntarily agree to participate in the clinical study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with serious underlying conditions that may cause low back or radiating leg pain (e.g., spinal , acute fractures, or vertebral dislocations).
  • Presence of progressive neurological deficits or severe neurological symptoms.
  • Pain primarily caused by non-spinal soft tissue conditions (e.g., tumors, fibromyalgia, rheumatoid arthritis, gout).
  • Presence of other chronic diseases that may interfere with the treatment outcomes or their interpretation (e.g., stroke, myocardial infarction, kidney disease, diabetic neuropathy, dementia, epilepsy).
  • Currently taking , , psychiatric medications, or other drugs that may affect study outcomes.
  • to acupuncture treatment or conditions making acupuncture unsafe: bleeding disorders, current anticoagulant therapy, or severe diabetes with high risk of infection.
  • Contraindications to herbal medicine or conditions making its use unsafe: disorders or post-surgical conditions affecting drug absorption, severe hepatic or renal disease (, ALT, γ-GTP, or serum creatinine more than twice the upper normal limit at screening).
  • Use of pain-altering medications such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or receipt of acupuncture treatment within 1 week prior to screening.
  • Pregnant or breastfeeding women, or those planning pregnancy.
  • Patients who underwent lumbar spine surgery within the last 3 months.
  • Participation in another clinical trial within 1 month prior to screening, or plans to participate in another clinical trial during this study or within 6 months of screening.
  • Difficulty in providing written .
  • Any other condition judged by the investigator to make participation in the study inappropriate.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Herbal Medicine Strategy Group

    Participants in this group will receive individualized herbal medicine prescriptions tailored to their clinical condition (symptoms, imaging, and response to treatment). Prescriptions, including type, dosage, and frequency, are determined by Korean medicine doctors based on clinical judgment. The herbal medicine will be taken orally for a total of 30 days, prescribed every 10 days over three clinic visits. All prescription details will be recorded in the CRF.

    Procedure: Herbal Medicine Strategy

  • Active comparator
    Standard Korean Medicine Treatment Group

    Participants in this group will receive standard Korean medicine treatments for chronic low back pain, including acupuncture, electroacupuncture, cupping, infrared therapy, moxibustion, and physical therapy. Treatments are provided twice weekly for 5 weeks (maximum 10 sessions), with slight adjustments allowed depending on symptom severity. Treatment protocols are based on clinician judgment, and all interventions and points used are recorded.

    Procedure: Standard Korean Medicine Treatment

Interventions

  • ProcedureHerbal Medicine Strategy

    A pragmatic intervention involving tailored herbal prescriptions created by Korean medicine doctors. The specific composition, dose, and duration of herbal medicine vary per patient, and prescriptions are adjusted according to clinical response.

  • ProcedureStandard Korean Medicine Treatment

    This includes the application of Korean medical procedures widely used for chronic low back pain: Acupuncture: Insertion of needles at 10-20 selected acupoints for 10-15 minutes. Electroacupuncture: Electrical stimulation at 3 Hz to 4 acupoints for 10-15 minutes. Infrared Therapy: Application of infrared rays from 30 cm for 10-15 minutes. Cupping: Wet or dry cupping at 2-4 points on the lower back. Moxibustion: Applied to two points near the painful area at 43±1°C for 10-15 minutes. Physical Therapy (ICT or TENS): Applied for 10-15 minutes focusing on the quadratus lumborum. Treatment frequency is 2 times/week for 5 weeks, but may be adjusted to 1-3 times/week depending on symptoms. Total number of sessions is limited to 10.

06

What researchers measure

Primary outcomes

  1. Low Back Pain Numeric Rating Scale (NRS)

    The primary outcome measure will be the change in the NRS score between Baseline and Week 7, which corresponds to the first follow-up visit after the end of treatment. The intensity of low back pain over the past week will be assessed using the NRS. In this scale, patients select a number from 0 to 10 that best represents their current level of discomfort (0 indicates no pain, and 10 indicates the worst pain imaginable).

    Time frame: Baseline(Week 0), Week 3, Week 5, Week 7, Week 12, Week 19, Week 26

  2. Oswestry Disability Index (ODI)

    The primary outcome measure will be the change in the ODI score between Baseline and Week 7, which corresponds to the first follow-up visit after the end of treatment. The functional status of participants will be evaluated using the ODI questionnaire, which was developed to assess the degree of disability caused by low back pain. The ODI consists of 10 items, each rated on a 6-point scale from 0 to 5. The total score is summed and then divided by the maximum possible score (50 points for 10 items) to calculate a percentage. A higher percentage indicates a greater level of disability. A validated Korean version of the ODI will be used in this study.

    Time frame: Baseline(Week 0), Week 3, Week 5, Week 7, Week 12, Week 19, Week 26

Secondary outcomes

  1. Radiating Leg Pain Numeric Rating Scale (NRS)

    The intensity of radiating leg pain over the past week will be assessed using the NRS. Participants will select a number from 0 to 10 that best represents their current level of discomfort (0 indicates no pain, and 10 indicates the most severe discomfort imaginable).

    Time frame: Baseline(Week 0), Week 3, Week 5, Week 7, Week 12, Week 19, Week 26

  2. Low Back Pain and Radiating Leg Pain Visual Analogue Scale (VAS)

    The VAS consists of a 100 mm horizontal line where one end represents "no pain" and the other end represents "worst pain imaginable." Participants will mark a point on the line corresponding to the intensity of their low back pain and radiating leg pain during the past week.

    Time frame: Baseline(Week 0), Week 7, Week 12, Week 19, Week 26

  3. Roland-Morris Disability Questionnaire-6 (RMDQ-6)

    The RMDQ-6 is a validated short-form version of the Roland-Morris Disability Questionnaire-24 (RMDQ-24) used to rapidly assess disability related to low back pain. It includes 6 items, and participants will respond based on their current condition. Higher scores indicate greater disability.

    Time frame: Baseline(Week 0), Week 7, Week 12, Week 19, Week 26

  4. Patient Global Impression of Change (PGIC)

    The PGIC is a 7-point scale used to subjectively assess the patient's overall impression of improvement. The scale includes the following categories: 1. = Very much improved, 2. = Much improved, 3. = Minimally improved, 4. = No change, 5. = Minimally worse, 6. = Much worse, 7. = Very much worse.

    Time frame: Week 7

  5. EQ-5D-5L (EuroQol-5 Dimension, 5-Level)

    The EQ-5D-5L is a widely used instrument for assessing health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has five levels of response. Weighted values are applied to each level to compute an index score representing the individual's overall health state.

    Time frame: Baseline(Week 0), Week 3, Week 7, Week 12, Week 19, Week 26

  6. Health-related Quality of Life Instrument with 8 Items (HINT-8)

    The HINT-8 is a Korean-specific instrument developed to measure health-related quality of life, covering physical, social, mental, and positive health dimensions. It includes 8 items: climbing stairs, pain, energy, work, depression, memory, sleep, and happiness. Participants will choose one of four response levels per item. For example, in the stair-climbing item: 1. = No difficulty, 2. = Some difficulty, 3. = Severe difficulty, 4. = Unable to climb stairs. For depression: 1. = Not depressed at all, 2. = Occasionally depressed, 3. = Frequently depressed, 4. = Always depressed.

    Time frame: Baseline(Week 0), Week 3, Week 7, Week 12, Week 19, Week 26

  7. Patient Health Questionnaire-15 (PHQ-15)

    The PHQ-15 is a validated Korean version of a 15-item questionnaire derived from the Patient Health Questionnaire (PHQ) used to assess general health status and somatic symptoms over the past 4 weeks. Each item is rated on a 3-point scale: 0 = Not bothered at all, 1. = Bothered a little, 2. = Bothered a lot. The total score ranges from 0 to 30 and reflects symptom severity: 0-4 = Minimal, 5-9 = Mild, 10-14 = Moderate, 15-30 = Severe. PHQ-15 is widely used to assess somatic symptom burden and is helpful in evaluating depression and somatoform disorders.

    Time frame: Baseline(Week 0), Week 7, Week 12, Week 19, Week 26

  8. Credibility and Expectancy

    Treatment expectation will be assessed using a 9-point Likert scale. At the screening visit, participants will be asked: "How much do you think traditional Korean medicine treatment will relieve your symptoms?" Response options range from: 1 = Not at all, 5 = Somewhat, 9 = Very much.

    Time frame: Screening Visit

  9. Economic evaluation question

    Cost data will be collected using a structured questionnaire designed to measure direct medical costs (e.g., medical services), non-medical costs (e.g., transportation, caregiver expenses), informal medical costs (e.g., health supplements, devices), and productivity losses. Productivity loss will be evaluated using the Work Productivity and Activity Impairment (WPAI) questionnaire, and economic costs will be estimated for cost-effectiveness analysis.

    Time frame: Baseline(Week 0), Week 3, Week 7, Week 12, Week 19, Week 26

  10. Drug Consumption

    Information on medications taken during the study period for current medical conditions will be collected at each visit, including drug name and dosage. Additionally, other treatments such as physical therapy or injections will be recorded by frequency.

    Time frame: Baseline(Week 0), Week 3, Week 5, Week 7, Week 12, Week 19, Week 26

Other outcomes

  1. Adverse Events

    Adverse events are defined as any undesirable and unintended signs (e.g., abnormal lab results), symptoms, or diseases occurring after study procedures, regardless of causality. Events will be collected through participant self-reports and investigator observation, and analyzed by frequency between groups. The relationship of each adverse event to the study treatment will be assessed using the WHO-UMC causality assessment scale: 1. = Certain, 2. = Probable/Likely, 3. = Possible, 4. = Unlikely, 5. = Conditional/Unclassified, 6. = Unassessable/Unclassifiable. Severity will also be categorized using Spilker's classification: Mild (1): No treatment needed; does not interfere with daily function. Moderate (2): Noticeable interference with daily function; may require treatment and recoverable. Severe (3): Requires intensive treatment; may result in sequelae.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 7, Week 12, Week 19, Week 26

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 14 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 10, 2025
StartActual
Oct 31, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07058376
Lead sponsor
Jaseng Medical Foundation
Responsible party
Sponsor
First posted
Jul 10, 2025
Start date
Oct 31, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

In-Hyuk Ha, PhD
principal investigator · Jaseng Medical Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion